Jersey's Cannabis Paradox: Grown Local, Stuck at the Border

September 25, 2026

Photo via Unsplash.

Green Island Growers in St Lawrence and Caprica in St Martin have spent years and, by most accounts, a fair amount of money clearing a regulatory bar that most cannabis producers never reach at all: GMP Part One certification, the tier of Good Manufacturing Practice that governs not just growing a plant but turning it into a finished medicine ready for a pharmacy shelf. Caprica picked up its MHRA certification in October 2025, joining Green Island in a very small club of Jersey cultivators who can point to a UK-recognised manufacturing standard next to their name.

And then nothing happened. Not because the companies fumbled the next step, but because there was no next step to take. By April 2026, Jersey's government had confirmed, in plain terms, that it could not actually issue the manufacturing licences that GMP Part One certification is supposed to unlock -- because the regulatory framework for granting them doesn't exist yet in usable form. So the island's growers keep doing what they've always done: shipping raw dried flower off-island, where companies in other jurisdictions process it, brand it, package it and sell it on to patients, pocketing the margin that comes with every one of those steps. Jersey grows the plant; someone else turns it into medicine and someone else again profits.

This is happening while local demand is doing anything but wait around. Prescriptions for medicinal cannabis products in Jersey climbed 35% in a single year, and the island's own GPs are writing more of them every quarter. The raw material is there. The certification is there. What's missing is the paperwork that would let Jersey actually keep any of the value it's growing.

Two Growers, One Missing Licence

Jersey's cannabis sector is small, locally rooted and, until recently, treated as something of a quiet success story. Green Island Growers, based in St Lawrence, and Caprica, based in St Martin, are both Jersey-owned cultivators that built their operations around eventually selling into the UK and European medical cannabis markets -- not just as flower suppliers but as licensed manufacturers of finished product. That distinction matters. A basic cultivation licence lets you grow and harvest. GMP Part One certification is a different animal entirely: it's the standard the MHRA applies to the manufacture and release of medicinal products intended for patients, the same tier of scrutiny applied to conventional pharmaceutical manufacturing. It covers everything from facility design and staff training to batch records and quality control systems capable of standing behind a product once it's in a patient's hands.

Caprica cleared that bar in October 2025, following Green Island's own certification, giving Jersey two GMP Part One-certified cannabis operations on an island of roughly 100,000 people -- a notable concentration by any measure. For an industry that has spent years lobbying UK and Jersey regulators to be taken seriously as a medical, not recreational, supply chain, certification at this level was meant to be the hard part.

Caprica founder Giles Castleton put it plainly to the Jersey Evening Post: GMP Part One was supposed to be the highest hurdle, the one that, once cleared, would leave government with a straightforward administrative task -- issue the manufacturer's licence and let the business get on with supplying pharmacies and wholesalers. Instead, both companies find themselves holding a certification with no licence to attach it to. The technical achievement is real. The commercial pathway it was supposed to open has not materialised, and neither company has been given a clear timeline for when it will.

Why the Government Says It Can't Issue the Licence

Health and Care Jersey's explanation, offered in April 2026, was unusually candid for a government department: an initial review of the island's medicines manufacturing licensing process found it not sufficiently robust, and work had only just begun on fixing it. In effect, officials acknowledged that the administrative machinery needed to convert a GMP Part One certification into an actual manufacturing licence had never been properly built -- not that it was slow, or backlogged, but that it wasn't functioning as a complete system.

Part of the tangle traces back to how Jersey's cannabis regulation is split across different legal tracks. Cultivation and production licensing falls under the authority of the Minister for Health and Social Services, a route that Green Island and Caprica navigated years ago to get growing in the first place. But refining a cannabis product into something that qualifies as a medicine -- the step that actually requires a manufacturing licence -- runs through a separate mechanism under the Medicines (Jersey) Law, one that involves the Chief Pharmacist's office directly. These aren't two stages of one process; they're two different regulatory lanes that were never fully connected, and a company can clear the growing lane entirely while finding the manufacturing lane still under construction.

That gap has not gone unnoticed by the people it's costing money. Green Island CEO Neel Sahai was blunt in his public criticism, telling the Jersey Evening Post that the delay was holding back a sector that had done everything asked of it. For a small island economy that has positioned medical cannabis as a genuine export opportunity -- not just a novelty crop -- having two GMP-certified manufacturers sidelined by an internal licensing gap is a pointed embarrassment, and one that's difficult to blame on the companies themselves.

Raw Flower Out, Finished Medicine In

Photo by CHUTTERSNAP via Unsplash.

In practice, this means Jersey's cannabis industry currently operates as a raw materials supplier rather than a finished-goods exporter. Dried flower leaves the island in bulk, destined for processors in other jurisdictions who extract it, formulate it into oils, capsules or other pharmaceutical presentations, package it under their own branding, and sell it into pharmacies and wholesale networks across Europe and the UK. Every one of those downstream steps -- extraction, formulation, packaging, branding, distribution -- carries its own margin, and none of that margin currently flows back to Jersey. The island is, functionally, growing the raw ingredient for someone else's finished product.

Castleton has been explicit about what a manufacturer's licence would change: once granted, Caprica could supply a local pharmacy, wholesaler or other licensed business directly from its Jersey facility, cutting out the need to route material through a third country's processing infrastructure before it comes anywhere near a patient. That's not a hypothetical efficiency gain -- it's the difference between Jersey capturing the value of a finished medicinal product and Jersey capturing the value of a farm commodity.

The trend lines make the stakes harder to ignore. A Freedom of Information report obtained from Health and Care Jersey in July 2026 showed export licences for raw cannabis material rising steadily even as import licences -- the kind that would bring finished cannabis medicines back onto the island for local dispensing -- were falling. Jersey is sending more of its product outward in unfinished form while bringing in less of the finished article that its own patients are prescribed. It's a lopsided trade pattern for an island with two companies certified to do the finishing work themselves, if only the licence existed to let them.

Demand Is Not the Problem

Medicinal cannabis prescriptions issued in Jersey rose sharply from 53,477 in 2024 to 72,065 in 2025, a jump of about 35%.

None of this is happening because Jersey patients have lost interest in medical cannabis. Quite the opposite. Doctors on the island prescribed more than 72,000 medicinal cannabis products in 2025 -- up from 53,477 the year before, a jump of 35% in twelve months. That's a striking growth curve for a jurisdiction of Jersey's size, and it puts roughly 4% of the island's adult population on a medical cannabis prescription, a proportion that would stand out in most European health systems.

Part of what's driving that uptake is structural. Unlike many jurisdictions where prescribing medical cannabis requires a specialist licence or referral to a narrow list of approved clinicians, Jersey GPs can prescribe it without any additional special authorisation. That relatively low clinical barrier has made cannabis-based treatment accessible through routine general practice rather than confined to a handful of specialist clinics, which helps explain why uptake has grown so quickly rather than plateauing at a small population of niche patients.

Jersey's position here isn't new-found enthusiasm -- it's the product of a head start most of the British Isles doesn't have. The island issued its first commercial cannabis cultivation licences in December 2020, marking the first commercial cultivation permitted anywhere in the British Isles since GW Pharmaceuticals began growing under licence back in 1998. That more-than-two-decade gap says something about how unusual Jersey's early move was, and it's part of why the island built a cultivation and export base fast enough to attract companies like Green Island and Caprica in the first place. The demand is real, the prescribing pathway is open, and the growers are certified. What's missing sits entirely on the regulatory side of the ledger.

Strip away the acronyms and what's left is a straightforward story: the certification Jersey's growers spent years chasing is sitting on a shelf, unused, because the government department responsible for the next step never finished building it. This isn't a case of regulators being cautious about cannabis as medicine, or demanding more safety data, or worrying about patient risk. Health and Care Jersey's own review found the licensing process not sufficiently robust -- an admission that the bottleneck is administrative, not scientific. That distinction matters, because it means the fix is entirely within the island's own control.

Every month the gap persists has a cost attached to it, even if that cost doesn't show up on a government balance sheet. It shows up in the export and import licence figures moving in opposite directions, in the finished-product margin landing in processing facilities outside Jersey rather than inside it, and in two companies holding top-tier manufacturing certifications with nothing to attach them to. Patients aren't going without medicine -- prescriptions are climbing regardless. But the island is quietly ceding the more valuable half of its own supply chain to whoever downstream is licensed to finish the job Jersey's growers are already equipped to do.

If Jersey wants its cannabis sector to be more than a feedstock supplier for pharmacies in other countries, the manufacturing licence framework needs to catch up to the companies that are already waiting on it -- not the other way around.